Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Confirmation of CD19+ B-Lymphocyte Depletion Prior to Intake of the Second Dose of Ocrelizumab in Multiple Sclerosis Patients
View through CrossRef
The aim of the retrospective study was to compare the immunophenotyping of T-lymphocytes, B-lymphocytes, and natural killer cells before the administration of the first and the second dose of ocrelizumab in 22 patients with multiple sclerosis in a three-year period (2019–2021) at the Department of Neurology of the University Hospital of Split. The values of cell immunophenotyping and protein electrophoresis, as well as laboratory parameters, were investigated. There was no significant decrease in serum albumin and globulins before the second dose of ocrelizumab (p > 0,05). A decrease in the number of T-lymphocytes before administration of the second dose of ocrelizumab was observed, but without statistical significance (p = 0.274). Significant depletion occurred in median CD19+ B-lymphocytes (p < 0.001) before the intake of the second dose of ocrelizumab confirming the primary action of ocrelizumab on the B cell lineage.
Title: Confirmation of CD19+ B-Lymphocyte Depletion Prior to Intake of the Second Dose of Ocrelizumab in Multiple Sclerosis Patients
Description:
The aim of the retrospective study was to compare the immunophenotyping of T-lymphocytes, B-lymphocytes, and natural killer cells before the administration of the first and the second dose of ocrelizumab in 22 patients with multiple sclerosis in a three-year period (2019–2021) at the Department of Neurology of the University Hospital of Split.
The values of cell immunophenotyping and protein electrophoresis, as well as laboratory parameters, were investigated.
There was no significant decrease in serum albumin and globulins before the second dose of ocrelizumab (p > 0,05).
A decrease in the number of T-lymphocytes before administration of the second dose of ocrelizumab was observed, but without statistical significance (p = 0.
274).
Significant depletion occurred in median CD19+ B-lymphocytes (p < 0.
001) before the intake of the second dose of ocrelizumab confirming the primary action of ocrelizumab on the B cell lineage.
Related Results
Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific
Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific
Introduction:
T cell bispecific antibodies (TCBs), such as blinatumomab, mosunetuzumab or glofitamab, redirect T cells toward cancer cells and rely on endogenous T c...
Treatment with natalizumab and ocrelizumab in multiple sclerosis
Treatment with natalizumab and ocrelizumab in multiple sclerosis
In this thesis, our research regarding personalized treatment with natalizumab and ocrelizumab in multiple sclerosis (MS) by extending treatment intervals and the road towards impl...
Divergence in CD19-Mediated Signaling Unfolds Intra-Clonal Diversity in Chronic Lymphocytic Leukemia Which Correlates with Disease Progression
Divergence in CD19-Mediated Signaling Unfolds Intra-Clonal Diversity in Chronic Lymphocytic Leukemia Which Correlates with Disease Progression
Abstract
Abstract 4570
Emerging data on intra-clonal diversity imply that this phenomenon may play a role in the clinical outcome of patients with chr...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Association of T lymphocytes level and clinical severity in patients of COVID-19 in Shenzhen China
Association of T lymphocytes level and clinical severity in patients of COVID-19 in Shenzhen China
To explore the correlation between T lymphocytes and clinical severity in patients of COVID-19. A total of 183 COVID-19 patients were recruited in Shenzhen Third People’s Hospital ...
The Loss of CD19 in Myeloma Cells Contributes to the Escape from FcγRII-Mediated Growth Suppression.
The Loss of CD19 in Myeloma Cells Contributes to the Escape from FcγRII-Mediated Growth Suppression.
Abstract
CD19 expression is specifically lost on human myeloma cells by the loss of Pax-5 gene expression, while normal plasma cells do express CD19. In order to exa...
Efficacy and safety of Ocrelizumab in comparison to placebo for multiple sclerosis: A systematic review and meta-analysis
Efficacy and safety of Ocrelizumab in comparison to placebo for multiple sclerosis: A systematic review and meta-analysis
Abstract
Objective:
This meta-analysis focuses on the combined results of all available trails and cohort studies reporting eff...
IKZF1 Deletion Confers Resistance to CAR19 in r/r B-ALL Via CD19 Intron Retention
IKZF1 Deletion Confers Resistance to CAR19 in r/r B-ALL Via CD19 Intron Retention
In recent years, CD19-directed chimeric antigen receptor T-cell (CAR19) therapy has provided a promising outcome for hematological malignancies, but a considerable number of patien...